A retrospective multicenter cohort study assessing the adherence rates and health outcomes across three academic centers
Latest Information Update: 21 Dec 2021
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Golimumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 21 Dec 2021 New trial record
- 27 Oct 2021 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021